Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott J. Rodig, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Scott Rodig and Frank Hodi.
Connection Strength

4.258
  1. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018 07 18; 10(450).
    View in: PubMed
    Score: 0.770
  2. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022 02; 23(2):279-291.
    View in: PubMed
    Score: 0.245
  3. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 03 11; 137(10):1353-1364.
    View in: PubMed
    Score: 0.231
  4. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight. 2020 06 18; 5(12).
    View in: PubMed
    Score: 0.220
  5. Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. Oncoimmunology. 2018; 7(7):e1440930.
    View in: PubMed
    Score: 0.188
  6. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017 11 30; 130(22):2420-2430.
    View in: PubMed
    Score: 0.182
  7. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res. 2017 06; 5(6):480-492.
    View in: PubMed
    Score: 0.178
  8. Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. Cancer Immunol Res. 2017 06; 5(6):446-454.
    View in: PubMed
    Score: 0.177
  9. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunol Res. 2017 01; 5(1):17-28.
    View in: PubMed
    Score: 0.173
  10. A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med. 2016 11; 5(11):3041-3050.
    View in: PubMed
    Score: 0.171
  11. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. Cancer Immunol Res. 2016 10; 4(10):858-868.
    View in: PubMed
    Score: 0.169
  12. Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. Am J Surg Pathol. 2016 Apr; 40(4):443-53.
    View in: PubMed
    Score: 0.164
  13. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncol. 2016 Apr; 2(4):518-22.
    View in: PubMed
    Score: 0.164
  14. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014 Jul; 2(7):632-42.
    View in: PubMed
    Score: 0.143
  15. Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4940.
    View in: PubMed
    Score: 0.060
  16. Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. NPJ Precis Oncol. 2021 Jun 29; 5(1):62.
    View in: PubMed
    Score: 0.059
  17. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217.
    View in: PubMed
    Score: 0.059
  18. Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discov. 2021 06; 11(6):1524-1541.
    View in: PubMed
    Score: 0.058
  19. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 05 01; 27(9):2470-2480.
    View in: PubMed
    Score: 0.058
  20. Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311.
    View in: PubMed
    Score: 0.055
  21. Author Correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019 Nov; 20(11):1556.
    View in: PubMed
    Score: 0.053
  22. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019 03; 20(3):326-336.
    View in: PubMed
    Score: 0.050
  23. Characterization of the Neuroendocrine Tumor Immune Microenvironment. Pancreas. 2018 10; 47(9):1123-1129.
    View in: PubMed
    Score: 0.049
  24. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
    View in: PubMed
    Score: 0.048
  25. Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. Cancer Immunol Res. 2017 11; 5(11):1046-1055.
    View in: PubMed
    Score: 0.046
  26. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. 2017 Sep 01; 123(17):3285-3290.
    View in: PubMed
    Score: 0.044
  27. Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. Lab Invest. 2017 02; 97(2):207-216.
    View in: PubMed
    Score: 0.043
  28. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. Cancer Immunol Res. 2016 12; 4(12):1038-1048.
    View in: PubMed
    Score: 0.043
  29. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
    View in: PubMed
    Score: 0.042
  30. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2016 08; 4(8):679-87.
    View in: PubMed
    Score: 0.042
  31. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017 08; 66(8):1463-1473.
    View in: PubMed
    Score: 0.041
  32. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17; 7:10501.
    View in: PubMed
    Score: 0.041
  33. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1726-35.
    View in: PubMed
    Score: 0.040
  34. PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res. 2015 Dec; 3(12):1308-15.
    View in: PubMed
    Score: 0.040
  35. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
    View in: PubMed
    Score: 0.040
  36. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res. 2015 Aug; 3(8):855-63.
    View in: PubMed
    Score: 0.039
  37. Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii11-iii12.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.